on behalf of the ROCnRAL ANRS 157 Study Group
Immunovirological consequences of a switch to a maraviroc/raltegravir dual therapy were analyzed in 16 HIV-infected patients with persistent viral load below 50 copies/ml. At 26-week postswitch, the CD4 R /CD8 R ratio decreased and the CD8 R T-cell activation increased. A decrease in classical monocytes was associated with a shift toward a proinflammatory monocyte profile and negatively correlated with ultrasensitive viral load. Thus, this therapeutic switch induced a proinflammatory profile probably driven by a slight loss of virus control.
Immune activation with an increase in inflammation markers, a decreased CD4 þ /CD8 þ ratio, expression of activation/exhaustion markers on T cells, and monocyte activation are biological hallmarks of HIV infection that may persist despite antiretroviral therapy (ART) induced viral suppression [1, 2] . These alterations are associated with the emergence of non-AIDS-related diseases in long-term-treated patients [3, 4] . T-cell activation [5] and ARTwith both nucleoside reverse transcriptase inhibitors (NRTI) and protease inhibitors [6, 7] have been associated with lipodystrophy in up to 40% of patients. Thus, the ROCnRAL Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS) 157 study (Clinical-Trials.gov: NCT1420523) was designed to evaluate whether a NRTI/protease inhibitors-sparing regimen such as maraviroc and raltegravir (MVC/RAL) could maintain viral suppression and be beneficial on both lipodystrophy and immune activation/inflammation parameters as suggested by others [8] [9] [10] [11] [12] [13] . However, the trial had to be stopped after a median duration of 19 weeks due to virological failure in five of 44 patients [14] .
The present immunological substudy could nevertheless be conducted to explore monocyte and T-cell activation in parallel to plasma soluble markers of activation and inflammation in a subgroup of volunteer patients maintaining a viral load below 50 copies/ml following the MVC/RAL switch. Sixteen patients were included and monitored at baseline (W0) but not all patients reached the end of treatment (eTT; median ¼ 26 weeks, range 12-40) because of the premature termination of the study. Changes in continuous variables were compared using paired Wilcoxon test. At baseline, median age was 55 years [interquartile range (IQR): 53/60], male/female sex 15/1, time since HIV diagnosis 24 years (IQR: [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , combination ART duration 17 years (IQR: 12/19), with a median duration of 5.2 years (IQR: 5.0/8.6) of suppressed HIV-viremia (<50 copies/ml), and CD4 þ nadir of 162 cells/mm 3 (IQR: 129/280). These clinical characteristics were similar to those of the total ROCn-RAL cohort [14] .
At W0, 13/16 patients had CD4 þ cell counts above 500/mm 3 (median ¼ 702, IQR: 559/798) and seven of 16 had CD8 þ cell counts above 700/mm 3 (median ¼ 994, IQR: 799/1012). At eTT compared with W0, CD4 and CD8 counts were similar despite a decrease in CD4 þ cell counts in eight of 13 patients, an increase in CD8 þ counts in six of 13 patients, and an overall decrease in the CD4 þ /CD8 þ ratios (median ¼ À0.10, IQR: À0.15/þ0.02, P ¼ 0.04, Fig. 1a ). Moreover, the number of CD38 molecules on CD8 þ T cells significantly increased (median ¼ þ296 sites/cell, IQR: þ4/þ791, P ¼ 0.02) reflecting activation of CD8 þ T cells, although HLA-DR expression remained unchanged ( Fig. 1b ).
MonocytesweresubdividedonthebasisofCD14andCD16 expression into classical
and nonclassical (CD14 low CD16 hi ) monocytes. At eTT, the percentage of classical monocytes decreased (median ¼ À6.7%, IQR:À2.0/À12.4, P ¼ 0.03) to the benefit of both intermediate and nonclassical monocytes, and CD14 expression significantly decreased on classical monocytes (median ¼ À48.8%, IQR: À41.7-62.1, P ¼ 0.01) ( Fig. 1c) . These characteristics suggested a progressive phenotypic shift from classical (CD14 þ ) to proinflammatory monocytes (CD14 low CD16 hi and CD14þCD16 þ/low ). In contrast, therewas no modification of HLA-DR or CD38 molecule expression on the monocyte subpopulations (data not shown).
Several soluble plasma molecules related to monocyte activation (sCD14, sCD163), monocyte recruitment (CCL4/MIP-1b, CXCL9/MIG, CXCL10/IP-10, CCL2/MCP-1), or cytokines monocyte production (interleukin-18, interleukin-6) were quantified. A decrease in sCD14 was observed (median ¼ À277 ng/ml, IQR: À386/À9, P ¼ 0.02), together with a trend toward a sCD163 increase (median ¼ þ59 ng/ml, IQR: À3/þ101, P ¼ 0.06), whereas there was no differences in cytokines/ chemokines levels between W0 and eTT ( Fig. 1d ).
Finally, the levels of ultrasensitive-HIV-1 viral load (threshold 1 copy/ml) [15] were measured at W0 and eTT despite the fact that all patients remained with viral load below 50 copies/ml. Among the 10/14 patients who had a viral load below 1 copy/ml at W0, four patients showed an increase ultrasensitive-HIV-1 viral load above 1 copy/ml at eTT. Among the four patients with detectable baseline ultrasensitive-HIV-1 viral load, two patients showed a higher eTT viral load (Fig. 1e) . Moreover, the eTT viral load levels were inversely correlated with the percentage of classical monocytes (Spearman's test, P ¼ 0.04, rho ¼ À0.77, Fig. 1f ), but not with CD38 expression on CD8 T cells (data not shown).
In summary, despite a limited number of patients, this immunological ROCnRAL substudy revealed that the switch to the dual MVC/RAL therapy, even in the absence of apparent viral failure, did not improve but even exaggerated the activation/inflammation status, as shown by, first, decreased CD4 þ /CD8 þ ratios with an increased CD38 expression on CD8 T cells and, second, a monocyte switch toward a proinflammatory phenotype with an increase of sCD163 plasma levels, contrasting with third, a decrease in sCD14 plasma levels.
There might be two potential explanations for this unfavorable biological outcome: first, a paradoxical effect of MVC on CD4 þ and CD8 þ T-cell activation and CD8 þ numbers in blood as previously reported, and presumably linked with an increase in circulating levels of CCR5 ligands [16] [17] [18] [19] , and, second, a loss of full control of HIV replication as shown by ultrasensitive real time-PCR and as attested by the number of patients with detectable replication even if below 50 copies/ml. The increase in CD8 þ CD38 þ cells and sCD163, two markers of HIV replication [20, 21] , are in favor of this second HIV replication scenario. In addition, the increase in proinflammatory monocytes, known as the main responders to viral Toll-like receptor (TLR) 7/8 ligands [22] , and the negative correlation between the classical monocyte percentages and ultrasensitive-HIV-1 viral load at eTT suggests this shift toward a proinflammatory monocyte profile could be driven by a TLR activation of viral origin. Altogether, these findings proposed that the MVC/RAL switch induces a loss of viral control conducting either to full relapses of virus replication in a few patients, or to low-level virus production in others, and participating to monocytes and T-cell activation and inflammation. sCD14, derived from membrane CD14 shedding, is a marker of monocyte activation mainly in response to TLR4/lipopolysaccharide signaling [23] and was suggested to reflect microbial translocation [24] . Decreased sCD14 plasma level has been reported after a switch to RAL therapy [17, 25, 26] . This decline, independently to TLR7/8 derived-monocyte activation might be related to the preservation of the intestinal barrier integrity and limitation of bacterial translocation as a consequence of an optimal penetration of RAL into the gut [27] .
In conclusion, this substudy highlighted a dual immunological profile induced by a switch to MVC/RAL therapy in lipohypertrophic ART-suppressed HIVinfected patients, with a favorable decline of CD14 shedding but an unfavorable monocyte and CD8 þ activation status that goes along with the previously reported poor viral outcome [14] . These data further stress the necessity that clinical trials evaluating new strategies should include immunological substudies in order to accurately evaluate their consequences on activation and inflammation markers.
